Conventional treatments have shown a limited efficacy for pancreatic cancer, and
immunotherapy is an emerging option for treatment of this highly fatal malignancy …

Response to cancer immunotherapy in primary versus metastatic disease has not been well-
studied. We found primary pancreatic ductal adenocarcinoma (PDA) is responsive to diverse …

Pancreatic cancer is a highly aggressive and deadly disease harboring a distinct population
of cancer stem cells (CSC) that is not affected by conventional therapies. A new therapeutic …

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive and deadly disease with an
overall 5-year survival rate of 13%(1). Current preclinical and clinical work is emerging to …

Pancreatic ductal adenocarcinoma (PDAC) is predicted to become the second most
common cause of cancer-related death in the United States by 2030. So far surgery remains …

Tumor antigens are crucial targets for T-cell-based therapy to induce tumor-specific
rejection. However, identifying pancreatic ductal adenocarcinoma (PDAC)-specific T-cell …

Unlike conventional MHC-reactive T cells, unconventional T cells have emerged as an
abundant component of the human immune system because of their role in tumor …

Pancreatic ductal adenocarcinoma (PDA) is a clinically challenging disease with limited
treatment options. Despite a small percentage of cases with defective mismatch DNA repair …

Background Emerging evidence has shown that intra-tumor immune features are associated
with response to immune checkpoint blockade (ICB) therapy. Accordingly, patient …

Pancreatic adenocarcinoma is a devastating disease and has an extremely poor prognosis.
Despite aggressive treatment approaches, including surgery, chemotherapy and radiation …